Latest Japan Approvals Include World-First For Pabinafusp
Other Nods For Vitrakvi, Polivy
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
